VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Inclusion Criteria: * Histologically confirmed endometrial carcinoma, meeting both of the following criteria: * Recurrent or persistent disease * Refractory to curative therapy or established treatments * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan * Tumors within a previously irradiated field are designated as nontarget lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days after completion of radiotherapy * Must have received one prior chemotherapeutic regimen for management of endometrial carcinoma (initial treatment may include high-dose therapy, consolidation therapy, or extended therapy administered after surgical or non-surgical assessment) * Not a candidate for a higher priority GOG protocol * No history or evidence of primary brain tumor or brain metastases * GOG performance status (PS) 0-2 (patients who received 1 prior regimen) OR GOG PS 0-1 (patients who received 2 prior regimens) * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Urine protein:creatinine ratio \< 1.0 OR urine protein \< 1.0 g by 24-hour urine collection * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * SGOT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * PT/PTT/INR ≤ 1.5 times ULN * In-range INR (between 2 and 3) allowed if patient is on a stable dose of therapeutic warfarin * QTc \< 500 msec * No evidence of serious ventricular arrhythmia * Ventricular tachycardia or ventricular fibrillation must be \< 3 beats in a row * LVEF normal * Ejection fraction ≥ 50% (for patients who received prior anthracycline, including doxorubicin hydrochloride and/or doxorubicin hydrochloride liposome) * No clinically significant cardiovascular disease, including any of the following: * Uncontrolled hypertension, defined as systolic blood pressure (BP) \> 140 mm Hg or diastolic BP \> 90 mm Hg * Myocardial infarction or unstable angina within the past 6 months * NYHA class II-IV congestive heart failure * Serious cardiac arrhythmia requiring medication * Peripheral vascular disease ≥ grade 2 * Cerebrovascular accident (i.e., CVA or stroke), transient ischemic attack, or subarachnoid hemorrhage within the past 6 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy * No HIV positivity * No neuropathy (sensory and motor) \> grade 1 * No active infection requiring antibiotics * No other invasive malignancies or any evidence of other cancer within the past 5 years except for nonmelanoma skin cancer * No serious nonhealing wound, ulcer, or bone fracture * No history of abdominal fistula or gastrointestinal perforation * No history or evidence of seizures not controlled with standard medical therapy * No intra-abdominal abscess within the past 28 days * No active bleeding or pathologic conditions that carry a high risk of bleeding (e.g., bleeding disorder, coagulopathy, or tumor involving major vessels) * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies * No significant traumatic injury within the past 28 days * No concurrent combination antiretroviral therapy for HIV-positive patients * Recovered from prior surgery * More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered * At least 1 week since prior hormonal therapy * Concurrent hormone replacement therapy allowed * At least 3 weeks since any other prior therapy, including immunologic agents * One additional prior cytotoxic regimen for management of recurrent or persistent endometrial cancer allowed * Cytotoxic regimens include any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa * More than 28 days since prior major surgery or open biopsy * More than 7 days since prior minor surgery, fine needle aspirates, or core biopsies * No prior cancer treatment that would preclude study compliance * No prior noncytotoxic chemotherapy for management of recurrent or persistent endometrial disease * No prior VEGF Trap or other VEGF pathway-targeted therapy * More than 5 years since prior radiotherapy to any portion of the abdominal cavity or pelvis except for the treatment of endometrial cancer * More than 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin * Patient must remain free of recurrent or metastatic disease * More than 5 years since prior chemotherapy for any abdominal or pelvic tumor except for the treatment of endometrial cancer * More than 3 years since prior adjuvant chemotherapy for localized breast cancer * Patient must remain free of recurrent or metastatic disease * Concurrent low-molecular weight heparin allowed for the prevention or treatment of venous thromboembolic disease if condition is considered clinically stable with treatment * No other concurrent investigational agents * No concurrent major surgery